This morning I received emails promoting Life Stem Genetics and linking to http://www.contrarianwealthcoalition.com/guide/LIFS.pdf
Disclosed budget: $300,000
Promoter: Contrarian Press
Paying party: Life Stem Genetics (the company being promoted)
Shares outstanding: 44,537,500
Previous closing price: $1.09
Market capitalization: $48 million
Excerpt from disclaimer:
The publisher, Contrarian Press, has been engaged by Life Stem Genetics to assist with the identification of potential market participants who may be interested in learning more about the company and its securities. The total budget for costs associated with that endeavor is $300,000 and the publisher will retain the excess, if any, after all costs are paid.
IMPORTANT NOTICE AND DISCLAIMER: This publication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. This publication, its publisher, and its editor
do not purport to provide a complete analysis of any company’s financial position. The publisher, Contrarian Press, has been engaged by Life Stem Genetics to assist with the identification of potential
market participants who may be interested in learning more about the company and its securities. The total budget for costs associated with that endeavor is $300,000 and the publisher will retain the
excess, if any, after all costs are paid. The publisher and editor are not, and do not purport to be, broker-dealers or registered investment advisors. Any investment should be made only after consulting
a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Investing in securities is speculative and carries a high
degree of risk. Past performance does not guarantee future results. This publication is based exclusively on information generally available to the public and does not contain any material, non-public
information. The information on which it is based is believed to be reliable. Nevertheless, the publisher cannot guarantee the accuracy or completeness of the information. This publication contains
forward-looking statements, including statements regarding expected continual growth of the featured company and/or industry. The publisher notes that statements contained herein that look forward
in time, which include everything other than historical information, involve risks and uncertainties that may affect the company’s actual results of operations. Factors that could cause actual results to differ
include the size and growth of the market for the company’s products and services, the ultimate degree of success in the company’s research and development, the company’s ability to fund its capital
requirements in the near term and long term, pricing pressures, etc. Natural Contrarian and Contrarian Press are trademarks of Scott S. Fraser and Natural Contrarian, Inc. All other trademarks used in this
publication are the property of their respective trademark holders. Natural Contrarian, Inc., Scott S. Fraser, and Contrarian Press are not affiliated, connected, or associated with, and are not sponsored,
approved, or originated by, the trademark holders unless otherwise stated. No claim is made by Natural Contrarian, Inc., Scott S. Fraser or the Contrarian Press to any rights in any third-party trademarks.
PDF copy of promotion website.
[Edit 2013-11-4]: I received a promotional email on LIFS this morning that linked to the following website: http://lifescience-wealth.com/. Oddly, there is no compensation listed on that website:
This publication is based exclusively on information generally available to the public and does not contain any material, non-public information. Information is obtained from sources believed to be reliable, but the information cannot be guaranteed as to its accuracy or completeness. The publisher is not, and does not purport to be, a registered investment adviser and did not accept compensation in return for this commentary. The objective of this newsletter is to present Situational Analysis and to provide progressive implementation of the author’s proprietary Situational Strategy Templates. No statement or expression of opinion, or any other matter herein, directly or indirectly, shall be construed as an offer to sell or the solicitation of an offer to buy the securities mentioned. Readers should not view this publication as offering personalized investment advice, and must individually determine the suitability of investments discussed for inclusion in their own portfolio. Past performance does not guarantee future results. Reprints or redistribution of this copyrighted material is allowed only by written permission from Contrarian Press LLC.
PDF copy of pump page.
[Edit 2013-11-18]: A promotion email this morning linked to the Andrew and Lynn Carpenter / Wall Street Revelator promotion page at www.lifsreport.com.
PDF copy of pump page
Excerpt from LIFSreport.com disclaimer:
Eclipse Media Group. has paid a total production budget of $1,789,000 for this advertising efforts. Andrew Carpenter’s Wall Street Revelator Advisor is paid seven thousand five hundred dollars as an editorial fee from Eclipse Media Group.
Full LIFSreport.com disclaimer:
IMPORTANT NOTICE AND DISCLAIMER: Andrew Carpenter’s Wall Street Revelator Advisory (WSR), does not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by WSR or an offer or solicitation to buy or sell any security. Eclipse Media Group. has used outside research and writers using public information to create the advertisement coming from WSR about Life stem Genetics, Inc. Although the information contained in this advertisement is believed to be reliable, WSR and Eclipse Media Group, make no warranties as to the accuracy of any of the content herein and accept no liability for how readers may choose to utilize the content. The opinions expressed in this advertisement and special report are solely those of WSR, unless otherwise referenced. Readers should perform their own due diligence, including consulting with a licensed, qualified investment professional or analyst. Further, readers are strongly urged to independently verify all statements made in this Special Report and perform extensive due diligence on this or any other mentioned company. Eclipse Meda Group. and WSR or affiliates are not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. Many states have established rules requiring the approval of a security by a state security administrator. Check with http://www.nasaa.org or call your state security administrator to determine whether a particular security is licensed for sale in your state. Many companies have information filed with state securities regulators and many will supply investors with additional information on request. Eclipse Media Group. has paid a total production budget of $1,789,000 for this advertising efforts. Andrew Carpenter’s Wall Street Revelator Advisor is paid seven thousand five hundred dollars as an editorial fee from Eclipse Media Group.. *More information can be received from Life Stem Genetics investor relations firm, or at Life Stem Genetics website lifestemgenetics.com. Further specific information, filings and disclosures as well as general investor information about publicly traded companies like Life Stem Genetics., advice to investors and other investor resources are available at the Securities and Exchange Commission website www.sec.gov and www.nasd.com. Any investment should be made only after consulting with a qualified investment advisor and after reviewing the publicly available financial statements of and other information about the company and verifying that the investment is appropriate and suitable. Investing in securities is highly speculative and carries a great deal of risk especially as to new companies with limited operations and no history of earnings. The information contained herein contains forward-looking information within the meaning of section 27a of the Securities Act of 1993, as amended, and section 21e of the Securities Exchange Act of 1934, as amended, including statements regarding expected growth of the featured company. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act, Life Stem genetics. notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the Company’s actual results of operations. Factors that could cause actual results to differ include the size and growth of the market, the Company’s ability to fund its capital requirements in the near term and in the long term; pricing pressures, technology issues, etc. Product names, logos, brands, and other trademarks featured or referred to within this report are the property of their respective trademark holders. These trademark holders are not affiliated with WSR.